Stocks · News reference
Dogwood Therapeutics Announces Completion Of 239-Patient Enrollment In Phase 2b Halneuron Trial For Chemotherapy Induced Neuropathic Pain; Topline Data Expected November 2026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dogwood Therapeutics Q2 EPS $(0.34) Misses $(0.14) Estimate
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.14) by 142.86 percent. This is a 82.91 percent increase over losses of $(1.99) per
8-K filing — Dogwood Therapeutics, Inc. (DWTX)
Filed: 2026-08-13 AccNo: 0001104659-26-095512 Size: 368 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits